FSDEA strengthens Institutional Partnerships in Huambo to Advance the National Pharmaceutical Industry
The delegation of the Angola Sovereign Wealth Fund (FSDEA), led by the Chairman of the Board of Directors, Armando Manuel, was received on Wednesday, 19 November, by the Governor of Huambo Province, Pereira Alfredo, as part of a follow-up visit to the provisional reception phase of the Ovihemba pharmaceutical factory.
During the meeting, the Governor expressed his satisfaction with the FSDEA’s active role in mobilising private investment for a project considered a priority for the province’s economic and social development. He emphasised that initiatives of this kind strengthen regional productive capacity, contribute to greater autonomy in the health sector, and support economic diversification.
Governor Pereira Alfredo also highlighted the structuring role of the FSDEA in the implementation of transformative projects, reaffirming the commitment of the provincial executive to support the consolidation and future operationalisation of the industrial unit.
For his part, the FSDEA Chairman, Armando Manuel, stated: 'The role of the FSDEA today is clear: to co-invest, to identify strategic initiatives and high-impact projects, and to create the conditions for the Sovereign Wealth Fund to aggregate resources and leverage its institutional convening power to accelerate their implementation.' He added that the FSDEA has several projects under development for the country and for the province, noting: 'This is our first project in the pharmaceutical sector, and we believe it will mark a historic milestone for the national pharmaceutical industry.'
The FSDEA delegation included Executive Directors Igor Lima, Alcides Safeca, Gabriel da Silva and Rui Ceita, Non-Executive Director Pedro Teta, as well as senior representatives from various departments. The audience also included investors from the Green Field FCR Fund, reinforcing institutional alignment and the shared commitment to the industrialisation and modernisation of the national pharmaceutical sector.
